8-K: ChromaDex Reports Second Quarter 2024 Results: Revenue Up 12%, Nears Breakeven

ChromaDex announced a 12% year-over-year increase in net sales to $22.7 million, achieving near breakeven net loss and positive Adjusted EBITDA of $1.6 million for the second quarter of 2024.

Summary

• ChromaDex reported a 12% increase in total net sales, reaching $22.7 million in the second quarter of 2024, compared to the same period last year.
• Tru Niagen sales contributed $18.6 million to the total, showing a 10% increase year-over-year.
• The company achieved a gross margin of 60.2%, slightly down from 60.8% in the prior year quarter.
• Operating expenses decreased by $0.7 million, or 5%, to $13.9 million due to lower general and administrative costs.
• ChromaDex reported a net loss of approximately breakeven, a $2.2 million improvement compared to the net loss of $2.2 million in the second quarter of 2023.
• Adjusted EBITDA improved to $1.6 million, up from $0.2 million in the same quarter last year.
• The company's cash flow from operating activities was approximately breakeven for the first six months of 2024, compared to a $6.1 million inflow in the prior year.
• ChromaDex expects full-year revenue growth between 10% and 15% year-over-year, with a slight improvement in gross margin.
• General and administrative expenses are projected to decrease by $1.5 million year-over-year.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and new product launches. The company's focus on scientific research and clinical trials adds to the positive sentiment. However, some risks and challenges are noted, preventing a perfect score.

Positives

• The company experienced a significant increase in total net sales, up 12% year-over-year.
• Tru Niagen sales also saw a solid increase of 10% year-over-year.
• ChromaDex achieved a substantial improvement in net loss, moving to approximately breakeven.
• Adjusted EBITDA showed a significant positive swing, reaching $1.6 million.
• The company received FDA Orphan Drug and Rare Pediatric Disease Designations for its nicotinamide riboside chloride product.
• The launch of Niagen+ and the NAD+ Test Kits expands the company's product offerings.
• The company expects continued revenue growth and reduced general and administrative expenses for the full year.

Negatives

• Gross margin percentage declined slightly by 60 basis points to 60.2% due to changes in business mix.
• Cash flow from operating activities decreased significantly compared to the prior year, driven by an increase in trade receivables and a reduction in accounts payable.

Risks

• The company faces risks related to inflationary and adverse economic conditions.
• ChromaDex has a history of operating losses and may need to obtain additional financing.
• The company relies on a limited number of third-party suppliers.
• There are risks associated with conducting business in China.
• The company needs to secure adequate quantities of pharmaceutical-grade Niagen.
• ChromaDex must obtain appropriate contracts with U.S. FDA-registered 503B outsourcing facilities.
• The company needs to maintain its position on the U.S. FDA Bulk Drug Substances list.
• There are risks associated with intellectual property protection and obtaining new patents.
• Clinical trials may be unsuccessful or insufficient to meet regulatory standards.
• The company may face challenges in enrolling sufficient subjects in clinical trials.
• There are risks associated with determinations made by the FDA and other governmental authorities.

Future Outlook

ChromaDex expects full-year revenue growth between 10% and 15% year-over-year, with a slight improvement in gross margin. Selling and marketing expenses will increase in absolute dollars but remain stable as a percentage of net sales. General and administrative expenses are expected to decrease by $1.5 million year-over-year.

Management Comments

• We delivered solid financial results in the second quarter, with $22.7 million in revenue and lower operating expenses resulting in virtually breakeven net loss and operating cash flows, as well as positive Adjusted EBITDA of $1.6 million, said ChromaDex Chief Executive Officer, Rob Fried.
• Moreover, we are thrilled to finally unveil our new product line, Niagen+, for healthcare practitioners and clinics. This launch marks a significant milestone for ChromaDex, as we believe we are the first company to offer NR in both oral and intravenous forms, reinforcing our position as the global authority in the NAD+ market.

Industry Context

ChromaDex's focus on NAD+ precursors and its expansion into intravenous and injectable forms of Niagen positions it as a leader in the growing market for healthy aging and metabolic health products. The launch of Niagen+ and the NAD+ Test Kits aligns with the trend of personalized medicine and the increasing demand for products that support cellular health.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, ChromaDex's 12% revenue growth and improvement to near breakeven net loss are positive indicators compared to other companies in the nutraceutical and bioscience sectors.
• The launch of Niagen+ in intravenous and injectable forms is a unique offering, differentiating ChromaDex from competitors primarily focused on oral supplements.
• The company's focus on scientific research and clinical trials, with over 97 registered studies, is a strong point compared to companies with less scientific backing.
• The Orphan Drug and Rare Pediatric Disease Designations for nicotinamide riboside chloride are significant achievements, potentially opening new market opportunities and revenue streams.

Related Party Transactions

• Trade receivables include $3.5 million and $2.8 million from related parties as of June 30, 2024 and December 31, 2023, respectively.

Stakeholder Impact

• Shareholders will likely view the improved financial results and positive outlook favorably.
• Employees may benefit from the company's growth and expansion.
• Healthcare practitioners will have access to new products and testing kits.
• Customers will have access to new and improved products.
• Suppliers may see increased demand for their products.

Next Steps

• ChromaDex plans to file an Investigational New Drug application with the U.S. FDA for nicotinamide riboside chloride.
• The company will pursue grant funding or other non-dilutive financing for human clinical trials.
• ChromaDex will continue to expand the availability of Niagen+ at select IV clinics.
• The company will continue to invest in research and development to drive future innovation.
• ChromaDex will focus on brand building initiatives and new market launches.

Key Dates

Keywords

ChromaDex, Niagen, Tru Niagen, nicotinamide riboside, NAD+, EBITDA, FDA, Orphan Drug Designation, Rare Pediatric Disease Designation, clinical trials, revenue, gross margin, operating expenses, healthcare practitioners, Ataxia Telangiectasia